MRNA Stock-Based Compensation
$349.00MTTM · USD
Period ending:
MRNA FY Stock-Based CompUSD
$483.00M$0.00
2016-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
MRNA stock-based compensation history
Non-cash compensation expense paid in equity. The available annual fiscal periods series contains 10 observations from Dec 31, 2016 to Dec 31, 2025.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 483,000,000 | |
| 429,000,000 | |
| 305,000,000 | |
| 226,000,000 | |
| 142,000,000 | |
| 93,000,000 | |
| 81,122,000 | |
| 72,565,000 | |
| 40,055,000 | |
| 39,360,000 |
Compare stock-based compensation
All MRNA financial metrics · MRNA stock overview · How to interpret financial metrics
